BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, Mak MS, Lai PB, Sung JJ, Chan HL. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79-87. [PMID: 17900247 DOI: 10.1111/j.1478-3231.2007.01576.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim KA, Kim MJ, Choi JY, Chung YE. Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination. Eur J Radiol. 2012;81:1450-1454. [PMID: 21514759 DOI: 10.1016/j.ejrad.2011.03.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
2 Costentin CE, Sogni P, Falissard B, Barbare JC, Bendersky N, Farges O, Goutte N. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C. Dig Dis Sci 2020;65:301-11. [PMID: 31346950 DOI: 10.1007/s10620-019-05724-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wong GLH. Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World J Hepatol 2015; 7(18): 2133-2135 [PMID: 26328024 DOI: 10.4254/wjh.v7.i18.2133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Chen W, Fernandes ML, Lin C, Lin S. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program: Delay in RFA for HCC Impacts Survival. J Surg Oncol 2011;103:133-9. [DOI: 10.1002/jso.21797] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
5 Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int. 2014;34 Suppl 1:139-145. [PMID: 24373091 DOI: 10.1111/liv.12394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
6 Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Giannini EG, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD; Italian Liver Cancer Group. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol 2014;61:333-41. [PMID: 24717522 DOI: 10.1016/j.jhep.2014.03.037] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 8.8] [Reference Citation Analysis]
7 Yoon YJ, Han K, Kim DY. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scandinavian Journal of Gastroenterology 2009;44:861-6. [DOI: 10.1080/00365520902903034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
8 Park YM, Jang JW, Yoo SH, Kim SH, Oh IM, Park SJ, Jang YS, Lee SJ. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat. 2014;21:171-177. [PMID: 24344773 DOI: 10.1111/jvh.12134] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
9 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Wei Q, Xu X, Ling Q, Zhou B, Zheng SS. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:251-255. [PMID: 23742769 DOI: 10.1016/s1499-3872(13)60041-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
12 Duininck G, Lopez-Aguiar AG, Lee RM, Miller L, Dariushnia S, Wu C, Alese OB, Lin JY, Wedd J, Adams A, Maithel SK, Russell MC. Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: The value of a multidisciplinary disease management team. J Surg Oncol 2019;120:1365-70. [PMID: 31642056 DOI: 10.1002/jso.25738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon DM, Loong HH, Yeo W, Chan AT. Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. Liver Int. 2012;32:271-278. [PMID: 22098536 DOI: 10.1111/j.1478-3231.2011.02634.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
14 Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766-2770. [PMID: 19267406 DOI: 10.1002/ijc.24281] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 10.4] [Reference Citation Analysis]
15 Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012;67:2766-2772. [PMID: 22899800 DOI: 10.1093/jac/dks269] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 6.7] [Reference Citation Analysis]
16 Sarkar M, Stewart S, Yu A, Chen MS, Nguyen TT, Khalili M. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat 2012;19:594-600. [PMID: 22762144 DOI: 10.1111/j.1365-2893.2011.01577.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
17 Harvin JA, Van Buren G, Tsao K, Cen P, Ko TC, Wray CJ. Hepatocellular carcinoma survival in uninsured and underinsured patients. J Surg Res 2011;166:189-93. [PMID: 20638680 DOI: 10.1016/j.jss.2010.04.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
18 Wai-sun Wong V, Lik-yuen Chan H. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Annals of Hepatology 2012;11:284-93. [DOI: 10.1016/s1665-2681(19)30922-6] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
19 Sung JJY, Tsoi KKF, Wong VWS, Li KCT, Chan HLY. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2008;28:1067-77. [DOI: 10.1111/j.1365-2036.2008.03816.x] [Cited by in Crossref: 260] [Cited by in F6Publishing: 242] [Article Influence: 18.6] [Reference Citation Analysis]
20 Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31:1095-1103. [PMID: 20180785 DOI: 10.1111/j.1365-2036.2010.04276.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 7.3] [Reference Citation Analysis]
21 Wong VW, Chan SL, Mo F, Chan T, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. JCO 2010;28:1660-5. [DOI: 10.1200/jco.2009.26.2675] [Cited by in Crossref: 290] [Cited by in F6Publishing: 106] [Article Influence: 24.2] [Reference Citation Analysis]
22 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 276] [Article Influence: 38.4] [Reference Citation Analysis]
23 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wong GL, Espinosa WZ, Wong VW. Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Clin Mol Hepatol 2015;21:200-11. [PMID: 26523265 DOI: 10.3350/cmh.2015.21.3.200] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
25 Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014;59:986-995. [PMID: 24123097 DOI: 10.1002/hep.26739] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 10.4] [Reference Citation Analysis]
26 Kennedy NA, Rodgers A, Altus R, McCormick R, Wundke R, Wigg AJ. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J 2013;43:772-7. [PMID: 23611607 DOI: 10.1111/imj.12166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
27 Magalhães-Costa P, Lebre L, Peixe P, Santos S, Chagas C. Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score. GE Port J Gastroenterol 2016;23:233-42. [PMID: 28868468 DOI: 10.1016/j.jpge.2016.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, Loffredo CA, Forgues M, Huang H, Xing XJ. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19:3944-3954. [PMID: 23719264 DOI: 10.1158/1078-0432.ccr-12-3363] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
29 Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2012;27:51-58. [PMID: 22004366 DOI: 10.1111/j.1440-1746.2011.06947.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
30 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624] [Cited by in Crossref: 364] [Cited by in F6Publishing: 339] [Article Influence: 45.5] [Reference Citation Analysis]
31 Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014;59:1471-81. [PMID: 24677195 DOI: 10.1002/hep.26944] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
32 Kim HY, Nam JY, Lee J, Lee HA, Chang Y, Lee HY, Cho H, Lee DH, Cho YY, Cho EJ, Yu SJ, Lee JM, Kim YJ, Yoon J. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther 2018;47:1490-501. [DOI: 10.1111/apt.14623] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
33 Wong GL, Chan HL, Yu Z, Wong CK, Leung C, Ho PP, Chan CY, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Chan HY, Tse CH, Wong VW. Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. J Gastroenterol Hepatol 2015;30:582-90. [PMID: 25252074 DOI: 10.1111/jgh.12779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
34 Liang LY, Wong VW, Toyoda H, Tse YK, Yip TC, Yuen BW, Tada T, Kumada T, Lee HW, Lui GC, Chan HL, Wong GL. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol 2020;55:899-908. [PMID: 32556643 DOI: 10.1007/s00535-020-01700-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Oeda S, Iwane S, Takasaki M, Furukawa NE, Otsuka T, Eguchi Y, Anzai K. Optimal Follow-up of Patients with Viral Hepatitis Improves the Detection of Early-stage Hepatocellular Carcinoma and the Prognosis of Survival. Intern Med. 2016;55:2749-2758. [PMID: 27725532 DOI: 10.2169/internalmedicine.55.6730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Clin Mol Hepatol 2017;23:239-48. [PMID: 28706177 DOI: 10.3350/cmh.2017.0008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
37 Majerović M, Jelaković M, Premužić M, Štromar IK, Radić D, Mance M, Pleština S, Ostojić R, Rustemović N, Krznarić Z. Hepatocellular Carcinoma Surveillance-Experience from Croatian Referral Centre for Chronic Liver Diseases. J Gastrointest Cancer 2019;50:48-53. [PMID: 29127665 DOI: 10.1007/s12029-017-0011-1] [Reference Citation Analysis]
38 Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1059-1068. [PMID: 20807216 DOI: 10.1111/j.1365-2036.2010.04447.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
39 Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013; 19(39): 6515-6522 [PMID: 24151375 DOI: 10.3748/wjg.v19.i39.6515] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
40 Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan WK, Gane E, Ong-Go AK, Lim SG, Ahn SH, Yu ML, Piratvisuth T, Chan HL;  Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5:776-787. [PMID: 32585136 DOI: 10.1016/s2468-1253(20)30190-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
41 Mittal S, Kanwal F, Ying J, Chung R, Sada YH, Temple S, Davila JA, El-Serag HB. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol 2016;65:1148-54. [PMID: 27476765 DOI: 10.1016/j.jhep.2016.07.025] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 12.8] [Reference Citation Analysis]
42 Toyoda H, Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG. Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31491-9. [PMID: 33295281 DOI: 10.1016/j.cgh.2020.10.033] [Reference Citation Analysis]
43 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
44 Kwon JW, Tchoe HJ, Lee J, Suh JK, Lee JH, Shin S. The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea. Gut Liver 2020;14:108-16. [PMID: 30974929 DOI: 10.5009/gnl18522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Wong GLH, Xu HX, Xie XY. Detection Of Focal Liver Lesions In Cirrhotic Liver Using Contrast-Enhanced Ultrasound. World J Radiol 2009; 1(1): 25-36 [PMID: 21160718 DOI: 10.4329/wjr.v1.i1.25] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
46 Wu C, Hsu Y, Ho HJ, Chen Y, Lee T, Lin J. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut 2016;65:693-701. [DOI: 10.1136/gutjnl-2014-308786] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
47 Meijer K, Haagsma EB. HCV-related liver cancer in people with haemophilia: HCV-RELATED LIVER CANCER IN HAEMOPHILIA. Haemophilia 2012;18:17-24. [DOI: 10.1111/j.1365-2516.2011.02575.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
48 Chen TM, Lin CC, Huang PT, Wen CF. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy. Tumour Biol. 2016;37:7129-7137. [PMID: 26662957 DOI: 10.1007/s13277-015-4593-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong C, Wong J, Lee K, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma: Meta-analysis: anti-viral therapy and HCC recurrence. Alimentary Pharmacology & Therapeutics 2011;33:1104-12. [DOI: 10.1111/j.1365-2036.2011.04634.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 10.5] [Reference Citation Analysis]
50 Sherman M. Surveillance for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:783-93. [DOI: 10.1016/j.bpg.2014.08.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
51 Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
52 Amarapurkar D, Han K, Chan HL, Ueno Y; The Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology 2009;24:955-61. [DOI: 10.1111/j.1440-1746.2009.05805.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
53 van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KM, Klümpen HJ, Jansen PL, IJzermans JN, van Oijen MG, Siersema PD. Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. J Hepatol. 2015;63:1156-1163. [PMID: 26100498 DOI: 10.1016/j.jhep.2015.06.012] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 10.9] [Reference Citation Analysis]
54 Han KH, Kim DY, Park JY, Ahn SH, Kim J, Kim SU, Kim JK, Lee KS, Chon CY. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study. J Clin Gastroenterol. 2013;47:538-544. [PMID: 23340065 DOI: 10.1097/mcg.0b013e3182755c13] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
55 Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010;55:826-835. [PMID: 19960258 DOI: 10.1007/s10620-009-1059-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
56 Imai E, Maruyama S. microRNA-Induced IgA Nephropathy. JASN 2012;23:765-6. [DOI: 10.1681/asn.2012030249] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416-424. [PMID: 23318478 DOI: 10.1038/ajg.2012.445] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
58 Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J 2021;62:758-66. [PMID: 34296554 DOI: 10.3349/ymj.2021.62.8.758] [Reference Citation Analysis]
59 Wong GL, Chan HL, Yiu KK, Lai JW, Chan VK, Cheung KK, Wong EW, Wong VW. Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:517-526. [PMID: 23305043 DOI: 10.1111/apt.12207] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
60 Kheraj R, Tewani SK, Ketwaroo G, Leffler DA. Quality improvement in gastroenterology clinical practice. Clin Gastroenterol Hepatol. 2012;10:1305-1314. [PMID: 22902758 DOI: 10.1016/j.cgh.2012.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
61 Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537-1547. [PMID: 23389810 DOI: 10.1002/hep.26301] [Cited by in Crossref: 295] [Cited by in F6Publishing: 283] [Article Influence: 32.8] [Reference Citation Analysis]
62 Xie C, Wu J, Yun J, Lai J, Yuan Y, Gao Z, Li M, Li J, Song L. MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS One 2013;8:e64235. [PMID: 23717574 DOI: 10.1371/journal.pone.0064235] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
63 Toyoda H, Yasuda S, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yamamoto S, Shiota S, Furoi M, Koyabu T, Furukawa D, Kumada T, Sumida Y. Impact of COVID-19 pandemic on surveillance of hepatocellular carcinoma: a study in patients with chronic hepatitis C after sustained virologic response. GastroHep 2020. [PMID: 32837333 DOI: 10.1002/ygh2.418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Zhou HY, Luo Y, Chen WD, Gong GZ. Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis. J Gastroenterol Hepatol. 2015;30:977-983. [PMID: 25689418 DOI: 10.1111/jgh.12917] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
65 Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N; ANRS CO12 CirVir study group. Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort. J Viral Hepat 2019;26:384-96. [PMID: 30380181 DOI: 10.1111/jvh.13029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
66 Liang LY, Wong VW, Tse YK, Yip TC, Lui GC, Chan HL, Wong GL. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1509-1517. [PMID: 31025388 DOI: 10.1111/apt.15269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
67 Toyoda H, Kumada T, Tada T, Mizuno K, Hiraoka A, Tsuji K, Ishikawa T, Akita T, Tanaka J. Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. Liver Int 2018;38:2260-8. [PMID: 29981527 DOI: 10.1111/liv.13927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
68 Campigotto M, Giuffrè M, Colombo A, Visintin A, Aversano A, Budel M, Masutti F, Abazia C, Crocé LS. Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature. World J Hepatol 2020; 12(12): 1239-1257 [PMID: 33442451 DOI: 10.4254/wjh.v12.i12.1239] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
69 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 982] [Article Influence: 156.8] [Reference Citation Analysis]
70 Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Wong VW. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144:933-944. [PMID: 23415803 DOI: 10.1053/j.gastro.2013.02.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 120] [Article Influence: 13.3] [Reference Citation Analysis]
71 Su F, Weiss NS, Beste LA, Moon AM, Jin GY, Green P, Berry K, Ioannou GN. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. J Hepatol 2021;74:850-9. [PMID: 33245934 DOI: 10.1016/j.jhep.2020.11.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
72 Limquiaco JL, Wong GL, Wong VW, Lai PB, Chan HL. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:63-69. [PMID: 19054256 DOI: 10.1111/j.1440-1746.2008.05701.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
73 Xu W, Yu J, Wong VW. Mechanism and prediction of HCC development in HBV infection. Best Practice & Research Clinical Gastroenterology 2017;31:291-8. [DOI: 10.1016/j.bpg.2017.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
74 Chen T, Chang T, Huang P, Tsai M, Lin L, Liu C, Ho K, Siauw C, Chao P, Tung J. Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter? Journal of Gastroenterology and Hepatology 2008;23:e179-88. [DOI: 10.1111/j.1440-1746.2008.05341.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
75 Yip TC, Wong GL, Wong VW, Tse YK, Liang LY, Hui VW, Lee HW, Lui GC, Chan HL. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol. 2020;72:847-854. [PMID: 31857194 DOI: 10.1016/j.jhep.2019.12.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
76 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Chan SL, Wong VW, Qin S, Chan HL. Infection and Cancer: The Case of Hepatitis B. J Clin Oncol. 2016;34:83-90. [PMID: 26578611 DOI: 10.1200/jco.2015.61.5724] [Cited by in Crossref: 81] [Cited by in F6Publishing: 41] [Article Influence: 11.6] [Reference Citation Analysis]
78 Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339-345. [PMID: 24128413 DOI: 10.1016/j.jhep.2013.09.029] [Cited by in Crossref: 155] [Cited by in F6Publishing: 130] [Article Influence: 17.2] [Reference Citation Analysis]
79 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
80 Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol. 2012;10:163. [PMID: 22897815 DOI: 10.1186/1477-7819-10-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
81 Haghshenas MR, Arabi M, Mousavi T. Hepatitis B genotypes in iran. Mater Sociomed 2014;26:129-33. [PMID: 24944540 DOI: 10.5455/msm.2014.26.129-133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
82 Ha J, Yan M, Aguilar M, Bhuket T, Tana MM, Liu B, Gish RG, Wong RJ. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer. 2016;122:2512-2523. [PMID: 27195481 DOI: 10.1002/cncr.30103] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
83 Zhao C, Xing F, Yeo YH, Jin M, Le R, Le M, Jin M, Henry L, Cheung R, Nguyen MH. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:406-19. [PMID: 31490419 DOI: 10.1097/MEG.0000000000001523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
84 Zheng H, Yang Y, Han J, Jiang WH, Chen C, Wang MC, Gao R, Li S, Tian T, Wang J, Ma LJ, Ren H, Zhou WP. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Sci Rep 2016;6:37070. [PMID: 27901021 DOI: 10.1038/srep37070] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]